Cargando…

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis

Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalen...

Descripción completa

Detalles Bibliográficos
Autores principales: Khandanpour, Cyrus, Eisfeld, Christine, Nimmagadda, Subbaiah Chary, Raab, Marc S., Weinhold, Niels, Seckinger, Anja, Hose, Dirk, Jauch, Anna, Försti, Asta, Hemminki, Kari, Hielscher, Thomas, Hummel, Manuela, Lenz, Georg, Goldschmidt, Hartmut, Huhn, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574071/
https://www.ncbi.nlm.nih.gov/pubmed/34760702
http://dx.doi.org/10.3389/fonc.2021.757664
_version_ 1784595545065521152
author Khandanpour, Cyrus
Eisfeld, Christine
Nimmagadda, Subbaiah Chary
Raab, Marc S.
Weinhold, Niels
Seckinger, Anja
Hose, Dirk
Jauch, Anna
Försti, Asta
Hemminki, Kari
Hielscher, Thomas
Hummel, Manuela
Lenz, Georg
Goldschmidt, Hartmut
Huhn, Stefanie
author_facet Khandanpour, Cyrus
Eisfeld, Christine
Nimmagadda, Subbaiah Chary
Raab, Marc S.
Weinhold, Niels
Seckinger, Anja
Hose, Dirk
Jauch, Anna
Försti, Asta
Hemminki, Kari
Hielscher, Thomas
Hummel, Manuela
Lenz, Georg
Goldschmidt, Hartmut
Huhn, Stefanie
author_sort Khandanpour, Cyrus
collection PubMed
description Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalence of 5-7% among healthy Caucasians and 10-15% in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) predisposing GFI-36N carriers to these diseases. Since GFI1 is implicated in B cell maturation and plasma cell (PC) development, we examined its prevalence in patients with multiple myeloma (MM), a haematological malignancy characterized by expansion of clonal PCs. Strikingly, as in MDS and AML, we found that the GFI1-36N had a higher prevalence among MM patients compared to the controls. In subgroup analyses, GFI1-36N correlates to a shorter overall survival of MM patients characterized by the presence of t(4;14) translocation and gain of 1q21 (≤3 copies). MM patients carrying gain of 1q21 (≥3 copies) demonstrated poor progression free survival. Furthermore, gene expression analysis implicated a role for GFI1-36N in epigenetic regulation and metabolism, potentially promoting the initiation and progression of MM.
format Online
Article
Text
id pubmed-8574071
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85740712021-11-09 Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis Khandanpour, Cyrus Eisfeld, Christine Nimmagadda, Subbaiah Chary Raab, Marc S. Weinhold, Niels Seckinger, Anja Hose, Dirk Jauch, Anna Försti, Asta Hemminki, Kari Hielscher, Thomas Hummel, Manuela Lenz, Georg Goldschmidt, Hartmut Huhn, Stefanie Front Oncol Oncology Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalence of 5-7% among healthy Caucasians and 10-15% in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) predisposing GFI-36N carriers to these diseases. Since GFI1 is implicated in B cell maturation and plasma cell (PC) development, we examined its prevalence in patients with multiple myeloma (MM), a haematological malignancy characterized by expansion of clonal PCs. Strikingly, as in MDS and AML, we found that the GFI1-36N had a higher prevalence among MM patients compared to the controls. In subgroup analyses, GFI1-36N correlates to a shorter overall survival of MM patients characterized by the presence of t(4;14) translocation and gain of 1q21 (≤3 copies). MM patients carrying gain of 1q21 (≥3 copies) demonstrated poor progression free survival. Furthermore, gene expression analysis implicated a role for GFI1-36N in epigenetic regulation and metabolism, potentially promoting the initiation and progression of MM. Frontiers Media S.A. 2021-10-25 /pmc/articles/PMC8574071/ /pubmed/34760702 http://dx.doi.org/10.3389/fonc.2021.757664 Text en Copyright © 2021 Khandanpour, Eisfeld, Nimmagadda, Raab, Weinhold, Seckinger, Hose, Jauch, Försti, Hemminki, Hielscher, Hummel, Lenz, Goldschmidt and Huhn https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Khandanpour, Cyrus
Eisfeld, Christine
Nimmagadda, Subbaiah Chary
Raab, Marc S.
Weinhold, Niels
Seckinger, Anja
Hose, Dirk
Jauch, Anna
Försti, Asta
Hemminki, Kari
Hielscher, Thomas
Hummel, Manuela
Lenz, Georg
Goldschmidt, Hartmut
Huhn, Stefanie
Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
title Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
title_full Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
title_fullStr Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
title_full_unstemmed Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
title_short Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
title_sort prevalence of the gfi1-36n snp in multiple myeloma patients and its impact on the prognosis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574071/
https://www.ncbi.nlm.nih.gov/pubmed/34760702
http://dx.doi.org/10.3389/fonc.2021.757664
work_keys_str_mv AT khandanpourcyrus prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT eisfeldchristine prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT nimmagaddasubbaiahchary prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT raabmarcs prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT weinholdniels prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT seckingeranja prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT hosedirk prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT jauchanna prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT forstiasta prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT hemminkikari prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT hielscherthomas prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT hummelmanuela prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT lenzgeorg prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT goldschmidthartmut prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis
AT huhnstefanie prevalenceofthegfi136nsnpinmultiplemyelomapatientsanditsimpactontheprognosis